We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Labopharm received an early approval from the FDA to market Oleptro, its novel once-daily formulation of the antidepressant trazodone. However, the firm is still exploring options for commercializing the drug in the U.S. and is looking for a partner.